Publications by authors named "Mark Shaefer"

Claim this Profile
L
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Edgar T Overton, Gary Richmond, Giuliano Rizzardini, Hans Jaeger, Catherine Orrell, Mark Shaefer

Lancet· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).
Vasiliki Chounta, Edgar T Overton, Anthony Mills, Susan Swindells, Paul D Benn, Mark S Shaefer

Patient· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Are We Hitting the Target? HIV Pre-Exposure Prophylaxis from 2012 to 2020 in the OPERA Cohort.
Karam C Mounzer, Jennifer S Fusco, Ricky K Hsu, Laurence Brunet, Vani Vannappagari, Mark S Shaefer

AIDS Patient Care STDS· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
"
"I feel empowered": women's perspectives on and experiences with long-acting injectable antiretroviral therapy in the USA and Spain.
Andrea Mantsios, Miranda Murray, Tahilin S Karver, Wendy Davis, David Margolis, Mark Shaefer

Cult Health Sex· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
To dose-adjust or not to dose-adjust: lamivudine dose in kidney impairment.
Karam Mounzer, Laurence Brunet, Christina M Wyatt, Jennifer S Fusco, Vani Vannappagari, Mark S Shaefer

AIDS· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks.
Miranda Murray, Antonio Antela, Anthony Mills, Jenny Huang, Hans Jäger, Mark Shaefer

AIDS Behav· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New genetic predictors for abacavir tolerance in HLA-B*57:01 positive individuals.
Rebecca Pavlos, Pooja Deshpande, Abha Chopra, Shay Leary, Kaija Strautins, Mark Shaefer

Hum Immunol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/min.
Lisa L Ross, A Sarah Walker, Yu Lou, Allan R Tenorio, Diana M Gibb, Mark S Shaefer

PLoS One· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir.
Kevin Robertson, Paul Maruff, Lisa L Ross, David Wohl, Catherine B Small, Mark S Shaefer

J Neurovirol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA-B*5701 Screening as a Risk-Mitigation Measure.
Chris M Stainsby, Teodora M Perger, Vani Vannappagari, Karam C Mounzer, Ricky K Hsu, Mark S Shaefer

Pharmacotherapy· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA observational database: a cohort study.
Karam Mounzer, Ricky Hsu, Jennifer S Fusco, Laurence Brunet, Cassidy E Henegar, Mark S Shaefer

AIDS Res Ther· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes from 2000 to 2009 in the Prevalence of HIV-1 Containing Drug Resistance-Associated Mutations from Antiretroviral Therapy-Naive, HIV-1-Infected Patients in the United States.
Lisa L Ross, Denise Shortino, Mark S Shaefer

AIDS Res Hum Retroviruses· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abacavir Use and Risk for Myocardial Infarction and Cardiovascular Events: Pooled Analysis of Data From Clinical Trials.
Cassandra Nan, Mark Shaefer, Rimgaile Urbaityte, James Oyee, Judy Hopking

Open Forum Infect Dis· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Sorbitol on the Pharmacokinetic Profile of Lamivudine Oral Solution in Adults: An Open-Label, Randomized Study.
Kimberly Adkison, Allen Wolstenholme, Yu Lou, Zhiping Zhang, Amy Eld, Mark Shaefer

Clin Pharmacol Ther· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects.
Catherine Butkus Small, David A Margolis, Mark S Shaefer, Lisa L Ross

BMC Infect Dis· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks.
Kathleen E Squires, Benjamin Young, Lizette Santiago, Robin H Dretler, Sharon L Walmsley, Mark S Shaefer

HIV AIDS (Auckl)· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimated glomerular filtration rates through 144 weeks on therapy in HIV-1-infected subjects receiving atazanavir/ritonavir and abacavir/lamivudine or simplified to unboosted atazanavir/abacavir/lamivudine.
Benjamin Young, Kathleen E Squires, Karen Tashima, Keith Henry, Stefan Schneider, Mark S Shaefer

HIV Clin Trials· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HIV-1 transmission patterns in antiretroviral therapy-naïve, HIV-infected North Americans based on phylogenetic analysis by population level and ultra-deep DNA sequencing.
Lisa L Ross, Joseph Horton, Samiul Hasan, James R Brown, Daniel Murphy, Mark S Shaefer

PLoS One· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial.
David A Wohl, Laveeza Bhatti, Catherine B Small, Howard Edelstein, Henry H Zhao, Mark S Shaefer

PLoS One· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES.
Benjamin Young, Kathleen E Squires, Lisa L Ross, Lizette Santiago, Louis M Sloan, Mark S Shaefer

AIDS Res Hum Retroviruses· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ARIES 144 week results: durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudine.
Kathleen E Squires, Benjamin Young, Edwin DeJesus, Nicholaos Bellos, Daniel Murphy, Mark S Shaefer

HIV Clin Trials· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Similar virologic and immunologic efficacy with fosamprenavir boosted with 100 mg or 200 mg of ritonavir in HIV-infected patients: results of the LESS trial.
Calvin Cohen, Edwin Dejesus, Anthony Lamarca, Benjamin Young, Linda Yau, Mark Shaefer

HIV Clin Trials· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.
Kathleen E Squires, Benjamin Young, Edwin Dejesus, Nicholaos Bellos, Daniel Murphy, Mark S Shaefer

AIDS· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients.
Kathleen E Squires, Benjamin Young, Edwin DeJesus, Nicholas Bellos, Daniel Murphy, Mark S Shaefer

HIV Clin Trials· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A study of HIV provider attitudes toward HLA-B 5701 testing in the United States.
Maria E Watson, Lisa G Patel, Belinda Ha, Paul Wannamaker, Robert Cuffe, Mark Shaefer

AIDS Patient Care STDS· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis